SOHO 2026 | Insights into the potential of moving towards TKI-sparing strategies in Ph+ ALL
Amin Azem
• 10 Sep 2026
Amin Azem, MD, Moffitt Cancer Center, Tampa, FL, discusses the potential to move toward chemotherapy-free, TKI-sparing strategies in Ph+ acute lymphoblastic leukemia (ALL), highlighting outcomes in patients treated with blinatumomab and ponatinib after TKI discontinuation. Dr Azem notes favorable overall survival outcomes in this cohort, while emphasizing the need for further research to identify a molecular signature that can predict relapse risk. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
